#1
#1 out of 1
health9h ago
Trial of multi-cancer blood test among 142,000 NHS patients fails to meet main aim
- The trial enrolled 142,942 NHS patients aged 50 to 77 with no cancer symptoms and followed them for three years.
- Results showed the primary endpoint—reduction in late-stage cancers—was not met.
- Some secondary findings suggested a potential decline in stage four cancers, yet experts urged caution.
- Grail described the findings as encouraging for some measures, while others remain uncertain.
- Independent experts cautioned that the main outcome was not met and results should be interpreted carefully.
- The trial was conducted within the NHS and presented at the ASCO annual meeting in Chicago.
- Experts emphasized that mortality outcomes will be informative in a couple of years.
- NHS England and NHS Improvement were involved in conducting the trial and evaluating its implications.
- The Galleri test is produced by Grail, which defended the study's potential despite the primary endpoint result.
- NHS leaders await detailed data to guide future decisions about population screening.
- Overall, the study did not demonstrate a clear population-level benefit for Galleri within the trial period.
Vote 0